Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
Document type:
Meeting Abstract
Author(s):
Stein, A.; Paschold, L.; Tintelnot, J.; Goekkurt, E.; Thuss-Patience, P. C.; Lorenzen, S.; Ettrich, T. J.; Knorrenschild, J. Riera; Jacobasch, L.; Kretzschmar, A.; Kubicka, S.; Al-Batran, S-E.; Reinacher-Schick, A.; Pink, D.; Sinn, M.; Lindig, U.; Hinke, A.; Becker, S. Hegewisch; Binder, M.